Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: BAD

Gene summary for BAD

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

BAD

Gene ID

572

Gene nameBCL2 associated agonist of cell death
Gene AliasBBC2
Cytomap11q13.1
Gene Typeprotein-coding
GO ID

GO:0000003

UniProtAcc

A0A024R562


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
572BADAEH-subject1HumanEndometriumAEH1.11e-12-2.60e-01-0.3059
572BADAEH-subject2HumanEndometriumAEH1.95e-06-2.58e-01-0.2525
572BADAEH-subject3HumanEndometriumAEH4.47e-07-1.68e-01-0.2576
572BADAEH-subject4HumanEndometriumAEH1.47e-06-2.53e-01-0.2657
572BADAEH-subject5HumanEndometriumAEH7.79e-14-3.91e-01-0.2953
572BADEEC-subject1HumanEndometriumEEC9.41e-18-3.33e-01-0.2682
572BADEEC-subject2HumanEndometriumEEC2.85e-06-2.21e-01-0.2607
572BADEEC-subject3HumanEndometriumEEC3.83e-39-4.12e-01-0.2525
572BADEEC-subject4HumanEndometriumEEC1.48e-06-2.43e-01-0.2571
572BADEEC-subject5HumanEndometriumEEC1.26e-03-2.44e-01-0.249
572BADGSM5276934HumanEndometriumEEC1.54e-17-3.89e-01-0.0913
572BADGSM5276937HumanEndometriumEEC1.66e-10-3.71e-01-0.0897
572BADGSM6177620_NYU_UCEC1_lib1_lib1HumanEndometriumEEC1.48e-25-4.68e-01-0.1869
572BADGSM6177620_NYU_UCEC1_lib2_lib2HumanEndometriumEEC1.12e-26-4.48e-01-0.1875
572BADGSM6177620_NYU_UCEC1_lib3_lib3HumanEndometriumEEC3.24e-30-4.48e-01-0.1883
572BADGSM6177621_NYU_UCEC2_lib1_lib1HumanEndometriumEEC3.56e-32-4.31e-01-0.1934
572BADGSM6177622_NYU_UCEC3_lib1_lib1HumanEndometriumEEC8.26e-43-4.73e-01-0.1917
572BADGSM6177622_NYU_UCEC3_lib2_lib2HumanEndometriumEEC3.92e-31-4.54e-01-0.1916
572BADGSM6177623_NYU_UCEC3_VisHumanEndometriumEEC5.00e-08-1.52e-01-0.1269
572BADLZE4THumanEsophagusESCC1.76e-216.87e-010.0811
Page: 1 2 3 4 5 6 7 8 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EndometriumThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AEH: Atypical endometrial hyperplasia
EEC: Endometrioid Cancer
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ProstateThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.BPH: Benign Prostatic Hyperplasia
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:000166619Oral cavityOSCCresponse to hypoxia177/7305307/187232.21e-117.50e-10177
GO:007099720Oral cavityOSCCneuron death202/7305361/187233.75e-111.23e-09202
GO:005160410Oral cavityOSCCprotein maturation170/7305294/187233.97e-111.28e-09170
GO:005254820Oral cavityOSCCregulation of endopeptidase activity235/7305432/187234.35e-111.40e-09235
GO:003629319Oral cavityOSCCresponse to decreased oxygen levels182/7305322/187231.14e-103.41e-09182
GO:007121416Oral cavityOSCCcellular response to abiotic stimulus186/7305331/187231.38e-104.10e-09186
GO:010400416Oral cavityOSCCcellular response to environmental stimulus186/7305331/187231.38e-104.10e-09186
GO:000183616Oral cavityOSCCrelease of cytochrome c from mitochondria46/730559/187231.17e-092.87e-0846
GO:004854520Oral cavityOSCCresponse to steroid hormone186/7305339/187231.86e-094.42e-08186
GO:190121420Oral cavityOSCCregulation of neuron death174/7305319/187231.09e-082.23e-07174
GO:20012449Oral cavityOSCCpositive regulation of intrinsic apoptotic signaling pathway44/730558/187231.22e-082.48e-0744
GO:00108227Oral cavityOSCCpositive regulation of mitochondrion organization53/730574/187231.26e-082.55e-0753
GO:001095019Oral cavityOSCCpositive regulation of endopeptidase activity107/7305179/187231.38e-082.78e-07107
GO:190165419Oral cavityOSCCresponse to ketone114/7305194/187231.82e-083.60e-07114
GO:00905598Oral cavityOSCCregulation of membrane permeability54/730578/187236.05e-081.09e-0654
GO:004578520Oral cavityOSCCpositive regulation of cell adhesion225/7305437/187236.06e-081.09e-06225
GO:00901997Oral cavityOSCCregulation of release of cytochrome c from mitochondria37/730548/187238.67e-081.52e-0637
GO:00105087Oral cavityOSCCpositive regulation of autophagy77/7305124/187231.59e-072.61e-0677
GO:00469028Oral cavityOSCCregulation of mitochondrial membrane permeability45/730563/187231.80e-072.92e-0645
GO:004211016Oral cavityOSCCT cell activation245/7305487/187232.00e-073.22e-06245
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa0502020EndometriumAEHPrion disease110/1197273/84652.39e-272.44e-251.78e-25110
hsa0520826EndometriumAEHChemical carcinogenesis - reactive oxygen species91/1197223/84653.28e-231.33e-219.76e-2291
hsa0501420EndometriumAEHAmyotrophic lateral sclerosis123/1197364/84652.17e-227.82e-215.72e-21123
hsa0501020EndometriumAEHAlzheimer disease124/1197384/84651.20e-203.91e-192.86e-19124
hsa0502220EndometriumAEHPathways of neurodegeneration - multiple diseases137/1197476/84659.27e-182.32e-161.70e-16137
hsa0451015EndometriumAEHFocal adhesion58/1197203/84654.99e-087.37e-075.39e-0758
hsa0472216EndometriumAEHNeurotrophin signaling pathway31/1197119/84654.07e-043.07e-032.25e-0331
hsa0491920EndometriumAEHThyroid hormone signaling pathway30/1197121/84651.20e-037.52e-035.50e-0330
hsa0541726EndometriumAEHLipid and atherosclerosis47/1197215/84651.24e-037.62e-035.58e-0347
hsa052158EndometriumAEHProstate cancer25/119797/84651.68e-031.01e-027.39e-0325
hsa0421010EndometriumAEHApoptosis30/1197136/84657.72e-034.05e-022.96e-0230
hsa0517018EndometriumAEHHuman immunodeficiency virus 1 infection43/1197212/84658.19e-034.22e-023.09e-0243
hsa05020110EndometriumAEHPrion disease110/1197273/84652.39e-272.44e-251.78e-25110
hsa05208112EndometriumAEHChemical carcinogenesis - reactive oxygen species91/1197223/84653.28e-231.33e-219.76e-2291
hsa05014110EndometriumAEHAmyotrophic lateral sclerosis123/1197364/84652.17e-227.82e-215.72e-21123
hsa05010110EndometriumAEHAlzheimer disease124/1197384/84651.20e-203.91e-192.86e-19124
hsa05022110EndometriumAEHPathways of neurodegeneration - multiple diseases137/1197476/84659.27e-182.32e-161.70e-16137
hsa0451016EndometriumAEHFocal adhesion58/1197203/84654.99e-087.37e-075.39e-0758
hsa0472217EndometriumAEHNeurotrophin signaling pathway31/1197119/84654.07e-043.07e-032.25e-0331
hsa04919110EndometriumAEHThyroid hormone signaling pathway30/1197121/84651.20e-037.52e-035.50e-0330
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
BADMYOFIBEsophagusADJFIBCD1,SLC22A23,S100A3, etc.0.00e+00The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
BADINCAFEsophagusADJFIBCD1,SLC22A23,S100A3, etc.0.00e+00The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
BADSMCEsophagusESCCFIBCD1,SLC22A23,S100A3, etc.5.49e-03The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
BADFIBEsophagusESCCFIBCD1,SLC22A23,S100A3, etc.0.00e+00The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
BADSNVMissense_Mutationc.351G>Ap.Met117Ilep.M117IQ92934protein_codingdeleterious(0)probably_damaging(0.966)TCGA-AC-A23H-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownPD
BADSNVMissense_Mutationc.293N>Ap.Arg98Hisp.R98HQ92934protein_codingdeleterious(0.03)possibly_damaging(0.688)TCGA-EK-A2RK-01Cervixcervical & endocervical cancerFemale>=65I/IIUnknownUnknownSD
BADSNVMissense_Mutationc.57G>Cp.Glu19Aspp.E19DQ92934protein_codingtolerated_low_confidence(1)benign(0.001)TCGA-4N-A93T-01Colorectumcolon adenocarcinomaMale>=65III/IVChemotherapyxelodaSD
BADSNVMissense_Mutationrs775688969c.74N>Ap.Ser25Asnp.S25NQ92934protein_codingtolerated(0.13)benign(0.409)TCGA-AA-A010-01Colorectumcolon adenocarcinomaFemale<65I/IIChemotherapyfolinicCR
BADSNVMissense_Mutationnovelc.212G>Tp.Ser71Ilep.S71IQ92934protein_codingdeleterious(0.01)possibly_damaging(0.857)TCGA-AJ-A5DW-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
BADSNVMissense_Mutationnovelc.401N>Tp.Ser134Ilep.S134IQ92934protein_codingdeleterious(0)probably_damaging(0.998)TCGA-AX-A1CE-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnspecificPaclitaxelSD
BADSNVMissense_Mutationnovelc.485N>Ap.Gly162Glup.G162EQ92934protein_codingdeleterious_low_confidence(0)probably_damaging(1)TCGA-AX-A2HC-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapypaclitaxelPD
BADSNVMissense_Mutationc.298N>Ap.Ala100Thrp.A100TQ92934protein_codingdeleterious(0)probably_damaging(0.999)TCGA-D1-A17R-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
BADSNVMissense_Mutationc.128G>Ap.Gly43Aspp.G43DQ92934protein_codingtolerated(0.08)probably_damaging(1)TCGA-FI-A2D5-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycarboplatinumPD
BADSNVMissense_Mutationc.483N>Tp.Arg161Serp.R161SQ92934protein_codingdeleterious_low_confidence(0)benign(0.272)TCGA-CH-5739-01Prostateprostate adenocarcinomaMale>=657UnknownUnknownSD
Page: 1 2 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
572BADKINASE, DRUGGABLE GENOMERUBOXISTAURINRUBOXISTAURIN18077363
572BADKINASE, DRUGGABLE GENOMEAT-101ISOSORBIDE
Page: 1